MEDI9447

PreclinicalSmall molecule

AstraZeneca

MEDI9447 is one of 12 small molecule programs targeting Carboplatin. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CarboplatinActive, not recruiting

CarboplatinPreclinical

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Carboplatin

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Approved

33 2

Taxol

Teva

Phase 3

17 3

Avastin

Roche

Phase 3

4 4

Herceptin

Roche

Phase 2

2 5

Perjeta

Roche

Phase 2

1 6

Zytiga

Johnson & Johnson

Phase 2

1 7

Jevtana

Sanofi

Phase 2

1 8

Rayos

RRoxane Laboratories

Phase 2

1 9

Serplulimab

Shanghai Henlius Biotech

Phase 2

1 10

Ivonescimab /kg

JJiangsu Cancer Institute & Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalActive, not recruiting

Triple-Negative Breast Cancer

NCT03616886

Clinical

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Active, not recruiting·JJules Bordet Institute·Preclinical·NCT03616886·129 enrolled

Unspecified1 trial

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03736473·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MEDI9447. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEDI9447 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEDI9447. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

MEDI9447

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News